Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma

We report data from prospective as well as retrospective and real world data studies and we analyze the safety and efficacy profile of everolimus as second-line therapy for mRCC. Although different drugs are currently available for the second-line treatment of mRCC, everolimus represents a feasible and safe option in this setting, especially for patients who have experienced high-grade toxicity or are still carrying TKI-related toxicities from first-line treatment.
Source: Therapeutic Advances in Urology - Category: Urology & Nephrology Authors: Tags: Reviews Source Type: research